| Hepatitis C: Somber Views of Natural History and Optimistic
Views of Interferon Treatment?
References
1. Darby SC, Ewart DW, Giangrande PLF, Spooner RJD, Rizza CR, Dusheiko
GM, Lee CA, et al. Mortality from liver cancer and liver disease
in haemophilic men and boys in UK given blood products contaminated
with hepatitis C. Lancet 1997; 350: 1425-1431[ [ Link previously at www.ncbi.nlm.nih.gov ]].
2. Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas
HC. Increase in primary liver cancer in the UK, 1979-1994. Lancet
1997; 350: 1142-1143.
3. Deuffic S, Poynard T, Buffat L, Valleron AJ. Trends in primary
liver cancer [Letter]. Lancet 1998; 351: 214-215.
4. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis
progression in patients with chronic hepatitis C. Lancet 1997; 349:
825-832[ [ Link previously at www.ncbi.nlm.nih.gov ]].
5. Deuffic S, Buffat L, Poynard T, Valleron AJ. La modelisation
de l'histoire naturelle de l'epidemie d'hepatite C permet de predire
une augmentation considerable de la mortalite par cancer primitif
du foie. Strasbourg. Assosiation Francaise pour Etude du Foie 1997.
6. Nishigushi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima
S, Shiomi S, et al. Randomised trial of effects of interferon-alfa
on incidence of hepatocellular carcinoma in chronic active hepatitis
C with cirrhosis. Lancet 1995; 346: 1051-1055[ [ Link previously at www.ncbi.nlm.nih.gov ]].
7. Kasahara A, Hayashi N, Mochizuki K, Takayanagi M, Yoshioka K,
Kakumu S, Iijima A, et al. Risk factors for hepatocellular carcinoma
and its incidence after interferon treatment in patients with chronic
hepatitis C. HEPATOLOGY 1998; 27: 1394-1402[.
8. Serfaty L, Aumaître H, Chazouillèrres O, Bonnan
A-M, Rosmorduc O, Poupon E, Poupon R, et al. Determinants of outcome
of compensated HCV-related cirrhosis. HEPATOLOGY 1998; 27: 1435-1440[Abstract].
9. Camma C, Giunta M, Linea C, Pagliaro L. The effect of interferon
on the liver in chronic hepatitis C: a quantitative evaluation of
histology by meta-analysis. J Hepatol 1997; 26: 1187-1199[ [ Link previously at www.ncbi.nlm.nih.gov ]].
10. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon
P, Zarski JP. Meta-analysis of interferon randomized trials in the
treatment of viral hepatitis C. Effects of dose and duration. HEPATOLOGY
1996; 24: 778-789[Abstract].
11. Degos F, Daurat V, Chevret S, Gayno S, Bastie A, Riachi G,
Ellouk AS, et al. Reenforced regimin of interferon alfa 2a reduces
the incidence of cirrhosis in patients with chronic hepatitis C:
a multicenter randomised trial. J Hepatol 1998;in press.
12. Fattovich G, Giustina G, Degos F, Tremolada F, Diaodati G,
Almasio P, et al. Morbidity and mortality in compensated cirrhosis
type C: a retrospective follow-up study of 384 patients. Gastroenterology
1997; 112: 463-472[Abstract].
13. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C,
Trepo C, Couzigou P, et al. A randomized trial of three 2b interferon
regimens for long term treatment of patients with chronic non-A
non-B hepatitis. N Eng J Med 1995; 332: 1457-1462[ [ Link previously at www.ncbi.nlm.nih.gov ]].
14. Davies G, Esteban-Mur R, Rustgi V, Hoefs J, Gordon S, Trepo
C, et al. Retreatment of relapse after interferon for chronic hepatitis
C: an international randomized controlled trial of interferon plus
ribavirin vs interferon alone [Abstract]. HEPATOLOGY 1997; 26: 247A.
Return To
Article
|
